Current News

Contact | Print version | Send article | RSS feed

S*BIO becomes Singapore's first biotech company to initiate clinical trial of novel anti-cancer drug

22 Jun 2007 - S*BIO Pte Ltd announced that it has become Singapore's first biotechnology company to initiate a Phase I clinical trial of a novel anti-cancer compound. The compound, SB939, belongs to a new class of targeted anti-cancer therapeutics called histone deacetylase (HDAC) inhibitors. SB939 is designed to be a "best-in-class" therapeutic amongst HDAC inhibitors being developed worldwide, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior oral availability and good tolerability.
 
The Phase I trial of SB939 is a dose-escalation study and is currently conducted at the Department of Hematology-Oncology, The Cancer Institute@National University Hospital (TCI@NUH) in Singapore. This study will evaluate the safety and tolerability, as well as determine the pharmacokinetic and pharmacodynamic profile of SB939 in cancer patients. SB939 has been found to be well tolerated in the first cohort of patients and the dosing continues with the next dose-groups. This clinical study involves patients with either solid or hematological tumors.